MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00415-025-13572-5

Медицинская библиотека · Journal of neurology · 2025

Plasma p-tau212 identifies cognitively unimpaired individuals with emerging amyloid-β pathology.

Kac Przemysław R, González-Escalante Armand, Milà-Alomà Marta, Ashton Nicholas J, Shekari Mahnaz, Ortiz-Romero Paula, Turton Michael, Harrison Peter, Zetterberg Henrik, Gispert Juan Domingo, Karikari Thomas K, Suárez-Calvet Marc, Blennow Kaj

СтатьяПеревод в очереди

Аннотация

Plasma phosphorylated-tau (p-tau) biomarkers show high performance as first-in-line tests in the evaluation of patients with cognitive symptoms and have also found utility in clinical trials for anti-amyloid drug therapies for Alzheimer's disease (AD). Plasma p-tau212 is a novel blood biomarker that can discriminate cognitively unimpaired (CU) and subjective cognitive decline patients from mild cognitive impairment (MCI)-AD and AD dementia patients in clinical cohorts. Using Simoa technology, we evaluated plasma p-tau212 for its ability to detect emerging amyloid-beta (Aβ) pathology in CU individuals with brain amyloidosis from CSF Aβ42/40 ratio (n = 317) or Aβ PET scans (n = 277). We benchmarked plasma p-tau212 against p-tau181, p-tau217, and p-tau231 by comparing their accuracies and fold changes for detecting brain amyloidosis. Our results showed that all the plasma p-tau biomarkers are increased in the CU CSF Aβ + participants, with the highest median fold change observed for plasma p-tau212. Discrimination performance of the biomarkers to differentiate amyloid PET-positive from amyloid PET-negative participants differed between plasma p-tau biomarkers, being higher for plasma p-tau217 and p-tau212 compared to plasma p-tau181 and p-tau231. Furthermore, plasma p-tau212 was elevated in participants with low Aβ burden (CSF Aβ-positive, amyloid PET-negative), supporting its potential as a cost-effective, easily implemented biomarker for trial recruitment in early stages. Its further increase in Aβ PET-positive participants suggests additional utility for monitoring anti-amyloid therapies.

Для цитирования: Kac Przemysław R, González-Escalante Armand, Milà-Alomà Marta, Ashton Nicholas J, Shekari Mahnaz, Ortiz-Romero Paula, Turton Michael, Harrison Peter, Zetterberg Henrik, Gispert Juan Domingo, Karikari Thomas K, Suárez-Calvet Marc, Blennow Kaj. Plasma p-tau212 identifies cognitively unimpaired individuals with emerging amyloid-β pathology.. Journal of neurology. 2025. DOI: 10.1007/s00415-025-13572-5.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.